Subscribe To
Usdjpy daily analysis – june 5, 2023
The USDJPY currency pair has experienced a significant pullback, reaching as low as 138.42. However, the subsequent bounce suggests that the pair rema...
June 5, 2023, 2:06 am
T. rowe price stuck in a holding pattern, with still plenty of fuel
T. Rowe Price receives a Hold rating based on a 5-step scoring system, with a score of 3. TROW stock is slightly overvalued and lacks revenue diversit...
June 5, 2023, 12:29 am
Global liquidity is going down: a projection for the rest of 2023
The future path of global liquidity presents a significant risk to the evolution of markets, warranting...
June 4, 2023, 11:59 pm
Day one announces new firefly-1 data for tovorafenib (day101) and initiation of rolling nda submission to fda for relapsed or progressive pediatric low-grade glioma
Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable ...
June 4, 2023, 4:45 pm
Why tesla and rivian soared, but nikola plunged, in may
Tesla's annual shareholder meeting brought some surprises last month. Rivian has plans to lower costs on its p...
June 4, 2023, 4:33 pm
Virtual reality industry excitement hits 'fever pitch' ahead of apple launch
Will Apple's planned mixed-reality headset lead to a virtual reality (VR) funding renaissance? That's the hope of startups in the VR space, accordin...
June 4, 2023, 4:33 pm
Astrazeneca's tagrisso slashes death risk in certain post-surgery lung cancer patients
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a...
June 4, 2023, 8:04 am
Drn: portfolio composition of this 3x leveraged fund fails to generate optimism
DRN suffered 53.5 percent price loss during the past one year. In the absence of any significant yield, its total return was equally ...
June 4, 2023, 6:37 am
Why is everyone talking about uipath stock?
Uipath has impressed stock market investors with its outperformance in recent quarters....
June 4, 2023, 5:45 am
Airbus seeing more predictable industrial rhythm after delays
European planemaker Airbus is seeing a more predictable pattern in its industrial activities and what a...
June 4, 2023, 5:44 am
Audusd weekly analysis – june 4, 2023
The AUDUSD currency pair has experienced a significant fall from its recent high at 0.7157, extending down to 0.6457. Market participants are now anti...
June 4, 2023, 3:44 am
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm